How to manage invasive procedures in children with haemophilia

Area of Science:

• Pediatric Hematology
• Surgical Hemostasis
• Factor Replacement Therapy

Background:

• Invasive procedures in children with haemophilia are generally safe with factor VIII/IX availability for non-inhibitor patients.
• Existing guidelines for surgical management are primarily based on adult data, lacking specific pediatric consensus.
• Children with inhibitors present a higher bleeding risk and require alternative treatments like bypassing agents.

Purpose of the Study:

• To review and synthesize literature on replacement therapy for pediatric haemophilia patients undergoing surgery.
• To address treatment considerations for both children with and without inhibitors.
• To focus on common clinical scenarios in pediatric haemophilia surgery.

Main Methods:

• Literature review of existing studies and expert opinions.
• Synthesis of data on factor replacement and bypassing agent use.
• Focus on surgical and post-operative management strategies.

Main Results:

• Safe surgical outcomes are achievable in children with haemophilia without inhibitors using factor concentrates.
• Children with inhibitors require careful management with bypassing agents, posing a higher bleeding risk.
• Optimal factor levels and therapy duration for pediatric surgery remain areas needing further consensus.

Conclusions:

• Replacement therapy is crucial for safe surgical interventions in children with haemophilia.
• Tailored treatment approaches are necessary for children with and without inhibitors.
• Further research is needed to establish definitive guidelines for pediatric haemophilia surgery.